Companies Dominating the Canine Leptospirosis Market
- Pfizer Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Baxter International Inc.
- Zoetic Pharmaceuticals Private Limited
- Boehringer Ingelheim International GmbH
- Sun Pharmaceuticals Industries Ltd
- Aurobindo Pharma
- King Pharmaceuticals
- Hikma Pharmaceuticals PLC
- Mylab Discovery Solutions
- Fresenius Kabi USA
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of canine leptospirosis is assessed at USD 1.01 billion.
The canine leptospirosis market size was over USD 957.6 million in 2024 and is projected to reach USD 2.14 billion by 2037, growing at around 6.4% CAGR during the forecast period i.e., between 2025-2037. Growing expansion of the pet population and high prevalence of leptospirosis will boost the market growth.
North America industry is likely to hold largest revenue share of 35% by 2037, due to rising substantial presence of drug manufacturers in the region.
The major players in the market include Pfizer Inc,Baxter International Inc.,Zoetic Pharmaceuticals Private Limited,Boehringer Ingelheim International GmbH,Sun Pharmaceuticals Industries Ltd,Aurobindo Pharma, King Pharmaceuticals,Hikma Pharmaceuticals PLC,Mylab Discovery Solutions,Fresenius Kabi USA.
